MXPA05003591A - Materiales basados en ciclodextrina, composiciones y usos relacionados a los mismos. - Google Patents

Materiales basados en ciclodextrina, composiciones y usos relacionados a los mismos.

Info

Publication number
MXPA05003591A
MXPA05003591A MXPA05003591A MXPA05003591A MXPA05003591A MX PA05003591 A MXPA05003591 A MX PA05003591A MX PA05003591 A MXPA05003591 A MX PA05003591A MX PA05003591 A MXPA05003591 A MX PA05003591A MX PA05003591 A MXPA05003591 A MX PA05003591A
Authority
MX
Mexico
Prior art keywords
cyclodextrin
compositions
based materials
uses related
active agents
Prior art date
Application number
MXPA05003591A
Other languages
English (en)
Spanish (es)
Inventor
Hwang Pun Suzie
Original Assignee
Insert Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Insert Therapeutics Inc filed Critical Insert Therapeutics Inc
Publication of MXPA05003591A publication Critical patent/MXPA05003591A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F13/00—Bandages or dressings; Absorbent pads
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
    • A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
    • A61L15/22—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing macromolecular materials
    • A61L15/28—Polysaccharides or their derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
    • A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
    • A61L15/42—Use of materials characterised by their function or physical properties
    • A61L15/44—Medicaments
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
    • A61L26/0009—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form containing macromolecular materials
    • A61L26/0023—Polysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
    • A61L26/0061—Use of materials characterised by their function or physical properties
    • A61L26/0066—Medicaments; Biocides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
    • A61L2300/252—Polypeptides, proteins, e.g. glycoproteins, lipoproteins, cytokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
    • A61L2300/258—Genetic materials, DNA, RNA, genes, vectors, e.g. plasmids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/60—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a special physical form
    • A61L2300/62—Encapsulated active agents, e.g. emulsified droplets
    • A61L2300/622—Microcapsules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/60—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a special physical form
    • A61L2300/62—Encapsulated active agents, e.g. emulsified droplets
    • A61L2300/626—Liposomes, micelles, vesicles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/80—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a special chemical form
    • A61L2300/802—Additives, excipients, e.g. cyclodextrins, fatty acids, surfactants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Materials Engineering (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Nanotechnology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Medical Informatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Other Resins Obtained By Reactions Not Involving Carbon-To-Carbon Unsaturated Bonds (AREA)
MXPA05003591A 2002-10-09 2003-10-08 Materiales basados en ciclodextrina, composiciones y usos relacionados a los mismos. MXPA05003591A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US41737302P 2002-10-09 2002-10-09
PCT/US2003/031991 WO2004032862A2 (en) 2002-10-09 2003-10-08 Cyclodextrin-based materials, compositions and uses related thereto

Publications (1)

Publication Number Publication Date
MXPA05003591A true MXPA05003591A (es) 2005-09-30

Family

ID=32094010

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA05003591A MXPA05003591A (es) 2002-10-09 2003-10-08 Materiales basados en ciclodextrina, composiciones y usos relacionados a los mismos.

Country Status (13)

Country Link
US (3) US8357377B2 (cg-RX-API-DMAC7.html)
EP (1) EP1549269A4 (cg-RX-API-DMAC7.html)
JP (1) JP4602085B2 (cg-RX-API-DMAC7.html)
KR (1) KR20050051686A (cg-RX-API-DMAC7.html)
CN (1) CN1717209A (cg-RX-API-DMAC7.html)
AU (1) AU2003295344B2 (cg-RX-API-DMAC7.html)
BR (1) BR0315198A (cg-RX-API-DMAC7.html)
CA (1) CA2501132A1 (cg-RX-API-DMAC7.html)
MX (1) MXPA05003591A (cg-RX-API-DMAC7.html)
RU (1) RU2005114007A (cg-RX-API-DMAC7.html)
TW (1) TW200423960A (cg-RX-API-DMAC7.html)
WO (1) WO2004032862A2 (cg-RX-API-DMAC7.html)
ZA (1) ZA200502754B (cg-RX-API-DMAC7.html)

Families Citing this family (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2277551E (pt) 2002-09-06 2013-08-22 Cerulean Pharma Inc Polímeros à base de ciclodextrina para a administração de medicamentos ligados por ligação covalente
BR0315198A (pt) 2002-10-09 2005-08-30 Insert Therapeutics Inc Materiais e composições à base de ciclodextrina e usos relacionados aos mesmos
SG129240A1 (en) * 2003-01-23 2007-02-26 Agency Science Tech & Res Biodegradable copolymer and nucleic acid delivery system
US7605120B2 (en) * 2003-10-22 2009-10-20 Amgen Inc. Antagonists of the brandykinin B1 receptor
US20070020298A1 (en) * 2003-12-31 2007-01-25 Pipkin James D Inhalant formulation containing sulfoalkyl ether gamma-cyclodextrin and corticosteroid
US20070020299A1 (en) 2003-12-31 2007-01-25 Pipkin James D Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid
AU2004311478A1 (en) 2003-12-31 2005-07-21 Cydex Pharmaceuticals, Inc. Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid
US20070020196A1 (en) * 2003-12-31 2007-01-25 Pipkin James D Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid prepared from a unit dose suspension
DE602004023765D1 (de) * 2004-03-12 2009-12-03 Trinity College Dublin Magnetoresistives medium
BRPI0512930A (pt) * 2004-07-01 2008-04-15 Netherlands Cancer Inst combinação compreendendo um inibidor de bcrp e 4-(4-metilpiperazin-1-ilmetil)-n[4-metil-3-(4-piridin-3-il)p irimidin-2-ilamino)fenil]-benzamida, composição farmacêutica, uso e embalagem comercial
ATE541928T1 (de) 2005-03-31 2012-02-15 Calando Pharmaceuticals Inc Inhibitoren der untereinheit 2 der ribonukleotidreduktase und ihre verwendungen
WO2006115211A1 (ja) * 2005-04-25 2006-11-02 Kaneka Corporation シクロデキストリン含有ポリエステル系重合体及びその製造方法
US20070021380A1 (en) * 2005-07-22 2007-01-25 Leonard Wiebe Novel drug delivery compositions
US20070160542A1 (en) * 2005-12-20 2007-07-12 Verus Pharmaceuticals, Inc. Methods and systems for the delivery of corticosteroids having an enhanced pharmacokinetic profile
US20070197486A1 (en) * 2005-12-20 2007-08-23 Verus Pharmaceuticals, Inc. Methods and systems for the delivery of corticosteroids
US20070178050A1 (en) * 2005-12-20 2007-08-02 Verus Pharmaceuticals, Inc. Methods and systems for the delivery of corticosteroids having an increased lung depositon
US20070185066A1 (en) * 2005-12-20 2007-08-09 Verus Pharmaceuticals, Inc. Systems and methods for the delivery of corticosteroids
US20070249572A1 (en) * 2005-12-20 2007-10-25 Verus Pharmaceuticals, Inc. Systems and methods for the delivery of corticosteroids
JP2007211060A (ja) * 2006-02-07 2007-08-23 Japan Advanced Institute Of Science & Technology Hokuriku 超分子ポリマー及びその合成方法
JP2009526858A (ja) * 2006-02-15 2009-07-23 ティカ レーケメデル アーベー コルチコステロイド溶液を製造する方法
KR100809046B1 (ko) * 2006-03-10 2008-03-03 가톨릭대학교 산학협력단 풀루란을 가진 나노자가응집체 및 이의 이용방법
US20080027212A1 (en) * 2006-06-28 2008-01-31 Skinner Keith K Methods and compositions for improved uptake of biological molecules
JP2010514679A (ja) * 2006-12-22 2010-05-06 スリーエム イノベイティブ プロパティズ カンパニー 制御放出組成物及び方法
US20080176958A1 (en) 2007-01-24 2008-07-24 Insert Therapeutics, Inc. Cyclodextrin-based polymers for therapeutics delivery
EP2130023B1 (en) 2007-03-15 2015-05-06 Ventana Medical Systems, Inc. Stabilized hematoxylin
CA2685331C (en) 2007-04-27 2016-07-05 Cydex Pharmaceuticals, Inc. Formulations containing clopidogrel and sulfoalkyl ether cyclodextrin and methods of use
US20100226987A1 (en) * 2007-06-28 2010-09-09 Capsutech Ltd. Targeting conjugates comprising active agents encapsulated in cyclodextrin-containing polymers
US12370352B2 (en) 2007-06-28 2025-07-29 Cydex Pharmaceuticals, Inc. Nasal and ophthalmic delivery of aqueous corticosteroid solutions
ITMI20071321A1 (it) * 2007-07-04 2009-01-05 Sea Marconi Technologies Di Va Nanospugne a base di ciclodestrine come veicolo per farmaci antitumorali
EP2283133A2 (en) 2008-04-04 2011-02-16 Calando Pharmaceuticals, Inc. Compositions and use of epas1 inhibitors
WO2010053487A1 (en) 2008-11-07 2010-05-14 Cydex Pharmaceuticals, Inc. Composition containing sulfoalkyl ether cyclodextrin and latanoprost
WO2010088286A1 (en) * 2009-01-28 2010-08-05 Smartcells, Inc. Synthetic conjugates and uses thereof
US20100197041A1 (en) * 2009-01-30 2010-08-05 Thomas Hermann Nucleic acid binding assays
US9845237B2 (en) * 2009-02-26 2017-12-19 The Regents Of The University Of California Supramolecular approach for preparation of size controllable nanoparticles
KR101991367B1 (ko) 2009-05-13 2019-06-21 사이덱스 파마슈티칼스, 인크. 프라수그렐 및 사이클로덱스트린 유도체를 포함하는 약학 조성물 및 그의 제조 및 사용 방법
US11020363B2 (en) 2009-05-29 2021-06-01 Cydex Pharmaceuticals, Inc. Injectable nitrogen mustard compositions comprising a cyclodextrin derivative and methods of making and using the same
AU2010253905B2 (en) 2009-05-29 2014-10-02 Cydex Pharmaceuticals, Inc. Injectable melphalan compositions comprising a cyclodextrin derivative and methods of making and using the same
US10045937B2 (en) * 2009-06-03 2018-08-14 Case Western Reserve University Therapeutic agent delivery system and method
IN2012DN02345A (cg-RX-API-DMAC7.html) 2009-09-16 2015-08-21 Univ Duke
CA2780779C (en) 2009-11-18 2020-02-04 Nektar Therapeutics Acid salt forms of polymer-drug conjugates and alkoxylation methods
US20110237540A1 (en) 2009-11-23 2011-09-29 Crawford Thomas C Cyclodextrin-based polymers for therapeutic delivery
US20110178287A1 (en) 2010-01-19 2011-07-21 Cerulean Pharma Inc. Cyclodextrin-based polymers for therapeutic delivery
CN105797168A (zh) * 2010-05-18 2016-07-27 天蓝制药公司 用于治疗自身免疫性疾病或其它疾病的组合物和方法
WO2012044832A1 (en) * 2010-09-30 2012-04-05 Fetzer Oliver S Methods of treating a subject and related particles, polymers and compositions
CA2816319C (en) 2010-11-01 2020-06-30 Marshall Edwards, Inc. Isoflavonoid compounds and methods for the treatment of cancer
WO2013013245A2 (en) * 2011-07-21 2013-01-24 The Regents Of The University Of California Catalytic delivery nanoubstrates (cdns) for highly efficient delivery of biomolecules
CN103289075B (zh) 2012-02-22 2016-01-20 天津键凯科技有限公司 聚乙二醇与纳洛酮的结合物及其药物组合物和应用
FR2989001B1 (fr) * 2012-04-06 2017-07-21 Centre Nat Rech Scient Microparticules et nanoparticules constituees de polysaccharides hydrophobises et d'une alpha-cyclodextrine
US9598503B2 (en) 2012-04-18 2017-03-21 Cerulean Pharma Inc. Methods and systems for polymer precipitation and generation of particles
US9827321B2 (en) 2012-08-14 2017-11-28 The Trustees Of The University Of Pennsylvania Stabilizing shear-thinning hydrogels
US20140094432A1 (en) 2012-10-02 2014-04-03 Cerulean Pharma Inc. Methods and systems for polymer precipitation and generation of particles
EP2925722A4 (en) * 2012-11-28 2016-07-06 Victoria Link Ltd COMPOUNDS WITH DENDRITIC CORE
CN105358136B (zh) * 2013-02-15 2018-11-13 加利福尼亚大学董事会 超分子磁性纳米粒子
US9321927B2 (en) 2013-02-27 2016-04-26 Crayola Llc Enhanced washability inks and methods of making the same
DE102013021060A1 (de) * 2013-12-18 2015-06-18 Rathor Ag Verfahren zur Abtrennung von Monomeren aus isocyanathaltigen Prepolymeren
US10329386B2 (en) 2014-07-08 2019-06-25 Osaka University Self-restoring macromolecular material and production method for same
GB2540914B (en) 2014-07-09 2021-11-24 Halliburton Energy Services Inc Treatment fluids for reducing subterranean formation damage
US10980774B2 (en) 2015-02-02 2021-04-20 Mei Pharma, Inc. Combination therapies
AU2016279912B2 (en) 2015-06-19 2020-07-09 The University Of Queensland Composition
CN105999289B (zh) * 2016-04-01 2018-11-20 南开大学 一种二元超两亲性纳米粒子溶液及其制备方法和应用
CN106349396A (zh) * 2016-08-26 2017-01-25 湖南尔康制药股份有限公司 一种具有超声敏感性的交联淀粉
US12447464B2 (en) 2016-12-22 2025-10-21 Duke University Polycationic microfibers and methods of using the same
CN112011040B (zh) * 2020-07-20 2021-08-17 广州医科大学 一种多重纳米传递系统及其制备方法
US20230285576A1 (en) 2020-08-05 2023-09-14 Ellipses Pharma Ltd Treatment of cancer using a cyclodextrin-containing polymer-topoisomerase inhibitor conjugate and a parp inhibitor
EP4297790A4 (en) * 2021-02-25 2025-01-01 Noble Panacea Labs, Inc. ORGANIC SUPRAMOLECULAR CONTAINER SET FOR CONTROLLED DRUG RELEASE

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1390479A (en) 1973-09-05 1975-04-16 I Orch Sinteza Akademii Nauk L Pharmaceutical composition for treatment of parkinsonism
DE2842862A1 (de) 1978-10-02 1980-04-10 Boehringer Mannheim Gmbh Verfahren zur bestimmung von ionen, polaren und/oder lipophilen substanzen in fluessigkeiten
CH663951A5 (fr) * 1984-10-10 1988-01-29 Nestle Sa Procede d'enrichissement selectif en acides gras polyinsatures d'un melange contenant des acides gras fractions enrichies obtenues et compositions les contenant.
US4841081A (en) 1985-10-16 1989-06-20 Osaka Soda Co., Ltd. Method of optically resolving a racemate or a diastereomeric mixture of glycidyl compound
GB2197720A (en) 1986-11-20 1988-05-25 Nat Res Dev Immobilisation of polynucleotides
EP0362290A4 (en) 1987-06-17 1991-09-25 Princess Margaret Children's Medical Research Foundation (Inc.) Cloning of mite allergens
US4877778A (en) 1987-07-01 1989-10-31 The Children's Medical Center Corporation Method of enhancing lipophile transport using cyclodextrin derivatives
JP2614081B2 (ja) 1988-05-27 1997-05-28 大塚化学株式会社 光学活性β−ラクタム誘導体の製造法
US4887778A (en) 1988-06-01 1989-12-19 Universal Instruments Corporation Feeder drive assembly and replaceable section for tape supplying and cover peeling
HU200913B (en) 1988-07-28 1990-09-28 Ciklodextrin Kutato Fejlesztoe Process for producing infusion stock-solution containing pharmaceutically active components of bad water solubility
US5098793A (en) * 1988-09-29 1992-03-24 Uop Cyclodextrin films on solid substrates
US5139687A (en) 1990-05-09 1992-08-18 The Proctor & Gamble Company Non-destructive carriers for cyclodextrin complexes
JPH0425505A (ja) 1990-05-21 1992-01-29 Toppan Printing Co Ltd シクロデキストリンポリマー及びシクロデキストリン膜の製造方法
CA2066633A1 (en) * 1990-11-30 1992-05-31 Masanobu Yoshinaga Processes for producing cyclodextrin derivatives and polymers containing immobilizing cyclodextrin therein
JP2976154B2 (ja) * 1991-11-27 1999-11-10 コニカ株式会社 ハロゲン化銀写真感光材料用固形処理剤
HU210922B (en) 1993-05-24 1995-09-28 Europharmaceuticals Sa Nimesulide alkali salt cyclodextrin inclusion complexes their preparation and pharmaceutical compositions containing them
US5880154A (en) 1994-02-01 1999-03-09 The Board Of Regents Of The University Of Nebraska Polymeric adamantane analogues
HU218280B (en) 1994-04-26 2000-07-28 Cyclodextrin inclusion complexes containing sin-1a which are stable intheir solid state, process for their preparation and pharmaceutical compositions containing the comlexes
US5691316A (en) 1994-06-01 1997-11-25 Hybridon, Inc. Cyclodextrin cellular delivery system for oligonucleotides
JP3699141B2 (ja) 1994-09-24 2005-09-28 伸彦 由井 超分子構造の生体内分解性医薬高分子集合体及びその調製方法
US5728804A (en) 1995-06-02 1998-03-17 Research Corporation Technologies, Inc. Use of cyclodextrins for protein renaturation
US6667293B1 (en) 1995-09-12 2003-12-23 Hybridon, Inc. Use of cyclodextrins to modulate gene expression with reduced immunostimulatory response
US5844030A (en) * 1996-07-09 1998-12-01 Andros; Nicholas Charged ion cleaning devices and cleaning system
DE19629494A1 (de) * 1996-07-09 1998-01-15 Schering Ag Pseudopolyrotaxane
WO1998047536A1 (en) 1997-04-23 1998-10-29 University Of Otago Controlled release of ophthalmic compositions
JPH11100401A (ja) 1997-07-30 1999-04-13 Kikkoman Corp 環状オリゴ糖及びそれを含むレトロウイルス性疾患の予防または治療剤
EA003832B1 (ru) 1997-09-15 2003-10-30 Дженетик Иммьюнити, Ллс. Ген-доставочный комплекс для чрескожной доставки чужеродного генетического материала в антиген-презентирующие клетки и способы его использования
IT1298732B1 (it) 1998-03-13 2000-02-02 Recordati Chem Pharm Composizioni farmaceutiche orali assumibili senza liquidi,contenenti complessi di inclusione
US6048736A (en) * 1998-04-29 2000-04-11 Kosak; Kenneth M. Cyclodextrin polymers for carrying and releasing drugs
US6509323B1 (en) 1998-07-01 2003-01-21 California Institute Of Technology Linear cyclodextrin copolymers
US7091192B1 (en) 1998-07-01 2006-08-15 California Institute Of Technology Linear cyclodextrin copolymers
US6261583B1 (en) * 1998-07-28 2001-07-17 Atrix Laboratories, Inc. Moldable solid delivery system
US6703381B1 (en) 1998-08-14 2004-03-09 Nobex Corporation Methods for delivery therapeutic compounds across the blood-brain barrier
AU2162700A (en) 1998-12-04 2000-06-26 California Institute Of Technology Supramolecular complexes containing therapeutic agents
US7375096B1 (en) 1998-12-04 2008-05-20 California Institute Of Technology Method of preparing a supramolecular complex containing a therapeutic agent and a multi-dimensional polymer network
US6740643B2 (en) 1999-01-21 2004-05-25 Mirus Corporation Compositions and methods for drug delivery using amphiphile binding molecules
EP1102784A4 (en) 1999-06-07 2009-12-30 Mirus Bio Corp A CONNECTION WITH A LABILES DISULFIDE TIE
EP1102785B1 (en) 1999-06-07 2013-02-13 Arrowhead Research Corporation COMPOSITIONS FOR DRUG DELIVERY USING pH SENSITIVE MOLECULES
EP1233671A4 (en) 1999-11-29 2005-11-02 Mirus Corp COMPOSITIONS AND METHODS OF DISPOSING MEDICAMENTS USING AMPHIPHILIC BINDING MOLECULARS
SK282717B6 (sk) 2000-03-10 2002-11-06 �Stav Experiment�Lnej Farmakol�Gie Sav Spôsob prípravy ultravysokomolekulových hyalurónanov
EP1307553A2 (en) 2000-08-01 2003-05-07 Oregon Health & Science University Mammalian dna binding membrane-associated protein-encoding gene and uses
TWI321054B (en) 2000-12-19 2010-03-01 California Inst Of Techn Compositions containing inclusion complexes
US7141540B2 (en) * 2001-11-30 2006-11-28 Genta Salus Llc Cyclodextrin grafted biocompatible amphilphilic polymer and methods of preparation and use thereof
PT2277551E (pt) 2002-09-06 2013-08-22 Cerulean Pharma Inc Polímeros à base de ciclodextrina para a administração de medicamentos ligados por ligação covalente
BR0315198A (pt) 2002-10-09 2005-08-30 Insert Therapeutics Inc Materiais e composições à base de ciclodextrina e usos relacionados aos mesmos
US20080176958A1 (en) 2007-01-24 2008-07-24 Insert Therapeutics, Inc. Cyclodextrin-based polymers for therapeutics delivery

Also Published As

Publication number Publication date
CN1717209A (zh) 2006-01-04
BR0315198A (pt) 2005-08-30
EP1549269A2 (en) 2005-07-06
CA2501132A1 (en) 2004-04-22
US20130315980A1 (en) 2013-11-28
US8357377B2 (en) 2013-01-22
WO2004032862A3 (en) 2004-07-01
AU2003295344B2 (en) 2008-01-31
EP1549269A4 (en) 2010-10-06
RU2005114007A (ru) 2005-10-10
WO2004032862A2 (en) 2004-04-22
KR20050051686A (ko) 2005-06-01
US20140199370A1 (en) 2014-07-17
TW200423960A (en) 2004-11-16
US20040109888A1 (en) 2004-06-10
JP4602085B2 (ja) 2010-12-22
ZA200502754B (en) 2006-09-27
JP2006513992A (ja) 2006-04-27
AU2003295344A1 (en) 2004-05-04

Similar Documents

Publication Publication Date Title
MXPA05003591A (es) Materiales basados en ciclodextrina, composiciones y usos relacionados a los mismos.
ATE264114T1 (de) Zyklodexrinpolymere zum gebrauch als medikamententräger
WO2005112886A3 (en) Methods and articles for the delivery of therapeutic agents
MY167123A (en) Conveniently implantable sustained release drug compositions
BR9914360A (pt) N-aralquilaminotetralinas como ligandos para oreceptor neuropeptìdeo yy5
EP1472230A4 (en) ANSAMYCINS WITH IMPROVED PHARMACOLOGICAL AND BIOLOGICAL PROPERTIES
WO2007040469A3 (en) Chloroquine coupled compositions and methods for their synthesis
MXPA05002814A (es) Formulacion para agentes lipofilicos.
WO2004093795A3 (en) Compositions for delivery of drug combinations
BRPI0416613A (pt) composição e forma de dosagem compreendendo uma molécula anfifìlica como um veìculo de suspensão
ATE295347T1 (de) Stoffe und zusammensetzungen für die verabreichung aktiver substanzen
WO2004052336A3 (en) High viscosity liquid controlled delivery system and medical or surgical device
DK1041072T3 (da) Dioxocyclopentylhydroxamsyrer
DE60312333D1 (de) Einen lipophilen wirkstoff enthaltende feste pharmazeutische zusammensetzung sowie deren herstellung
ATE396967T1 (de) (5-(2-hydroxy-4-chlorbenzoyl)valeriansäure und deren salze, und zusammensetzungen zur zuführung von wirkstoffen, die diese verbindungen enthalten
ATE345775T1 (de) Zusammensetzungen zur verabreichung von arzneimittelkombinationen
ATE470443T1 (de) Indol-1-yl-essigsäurederivate
ATE253820T1 (de) Wirkstoffhaltige komposition sowie deren herstellung und verwendung
FR2884252B1 (fr) Nouveaux derives d'isoindoles, compositions les contenant, leur preparation et leurs utilisations pharmaceutiques notamment en tant qu'inhibiteurs d'activites de la proteine chaperone hsp90
SE9603480D0 (sv) Beredningsform för svårlösliga läkemedel
DZ3459A1 (fr) Derives de 2h-1-benzopyran, procedes de preparation de ces derniers et compositions pharmaceutiques dans lesquels ils entrent.
IL144199A0 (en) Novel bretylium compositions and kits, and their use in preventing and treating cardiovascular conditions
NO20082848L (no) Farmasoytisk formulering for behandling av osteoartritt inneholdende klodronsyre og hyaluronsyre
FR2846327B1 (fr) Derives de n-benzodioxolyl, n-benzodioxanyl et n-benzodioxepinyl arylcarboxamides utilisables dans le traitement de dyslipidemies et compositions pharmaceutiques les contenant.
BR0206960A (pt) Composição farmacêutica oral, e, uso de um polìmero de ftalato de hidroxipropilmetilcelulose

Legal Events

Date Code Title Description
FA Abandonment or withdrawal